Prevalence of clinically actionable genotypes and medication exposure of older adults in the community
Nilofar Daneshi,1,2 Elizabeth Holliday,3,4 Stephen Hancock,3,4 Jennifer J Schneider,1,2 Rodney J Scott,1,2,5 John Attia,3,4 Elizabeth A Milward1,2 1Faculty of Health and Medicine, School of Biomedical Sciences and Pharmacy, 2Faculty of Health and Medicine, Centre for Bioinformatics, Biomarker Discov...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-01-01
|
| Series: | Pharmacogenomics and Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/prevalence-of-clinically-actionable-genotypes-and-medication-exposure--peer-reviewed-article-PGPM |
| _version_ | 1818549131350638592 |
|---|---|
| author | Daneshi N Holliday E Hancock S Schneider JJ Scott RJ Attia J Milward EA |
| author_facet | Daneshi N Holliday E Hancock S Schneider JJ Scott RJ Attia J Milward EA |
| author_sort | Daneshi N |
| collection | DOAJ |
| description | Nilofar Daneshi,1,2 Elizabeth Holliday,3,4 Stephen Hancock,3,4 Jennifer J Schneider,1,2 Rodney J Scott,1,2,5 John Attia,3,4 Elizabeth A Milward1,2 1Faculty of Health and Medicine, School of Biomedical Sciences and Pharmacy, 2Faculty of Health and Medicine, Centre for Bioinformatics, Biomarker Discovery and Information-Based Medicine, The University of Newcastle, Callaghan, 3Clinical Research Design, IT and Statistical Support Unit, Hunter Medical Research Institute, 4Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, Faculty of Health, University of Newcastle, 5Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW, Australia Abstract: This study analyzed clinically actionable pharmacogenotypes for clopidogrel, warfarin, statins, thiopurines, and tacrolimus using microarray data for 2121 participants (55–85 years) from the Australian Hunter Community Study (HCS). At least 74% of participants (95% confidence interval [CI]: 72%–76%) had strong level evidence for at least one medium- or high-risk actionable genotype that would trigger a change in standard therapy under current international recommendations. About 14% of these participants (95% CI: 12%–16%) were taking medication potentially affected by the genotype in question. Furthermore, ~2.6% of all participants with medication data (95% CI: 1.4%–3.8%) had a high-risk clinically actionable genotype for a medication to which they were exposed. This represents a considerable number of people at the population level. Although relationships between genotype and health outcomes remain contentious, pharmacogenotyping of multiple variants simultaneously may have considerable potential to improve medication safety and efficacy for older people in the community. Keywords: actionable genotype, community, older adults, pharmacogenomics, pre-emptive genotyping, single-nucleotide polymorphism |
| first_indexed | 2024-12-12T08:29:25Z |
| format | Article |
| id | doaj.art-4c1ef34467a74f2cae59fc609bc608c2 |
| institution | Directory Open Access Journal |
| issn | 1178-7066 |
| language | English |
| last_indexed | 2024-12-12T08:29:25Z |
| publishDate | 2017-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Pharmacogenomics and Personalized Medicine |
| spelling | doaj.art-4c1ef34467a74f2cae59fc609bc608c22022-12-22T00:31:09ZengDove Medical PressPharmacogenomics and Personalized Medicine1178-70662017-01-01Volume10172731064Prevalence of clinically actionable genotypes and medication exposure of older adults in the communityDaneshi NHolliday EHancock SSchneider JJScott RJAttia JMilward EANilofar Daneshi,1,2 Elizabeth Holliday,3,4 Stephen Hancock,3,4 Jennifer J Schneider,1,2 Rodney J Scott,1,2,5 John Attia,3,4 Elizabeth A Milward1,2 1Faculty of Health and Medicine, School of Biomedical Sciences and Pharmacy, 2Faculty of Health and Medicine, Centre for Bioinformatics, Biomarker Discovery and Information-Based Medicine, The University of Newcastle, Callaghan, 3Clinical Research Design, IT and Statistical Support Unit, Hunter Medical Research Institute, 4Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, Faculty of Health, University of Newcastle, 5Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW, Australia Abstract: This study analyzed clinically actionable pharmacogenotypes for clopidogrel, warfarin, statins, thiopurines, and tacrolimus using microarray data for 2121 participants (55–85 years) from the Australian Hunter Community Study (HCS). At least 74% of participants (95% confidence interval [CI]: 72%–76%) had strong level evidence for at least one medium- or high-risk actionable genotype that would trigger a change in standard therapy under current international recommendations. About 14% of these participants (95% CI: 12%–16%) were taking medication potentially affected by the genotype in question. Furthermore, ~2.6% of all participants with medication data (95% CI: 1.4%–3.8%) had a high-risk clinically actionable genotype for a medication to which they were exposed. This represents a considerable number of people at the population level. Although relationships between genotype and health outcomes remain contentious, pharmacogenotyping of multiple variants simultaneously may have considerable potential to improve medication safety and efficacy for older people in the community. Keywords: actionable genotype, community, older adults, pharmacogenomics, pre-emptive genotyping, single-nucleotide polymorphismhttps://www.dovepress.com/prevalence-of-clinically-actionable-genotypes-and-medication-exposure--peer-reviewed-article-PGPMActionable genotypeCommunityOlder adultsPharmacogenomicsPre-emptive genotypingSingle nucleotide polymorphism |
| spellingShingle | Daneshi N Holliday E Hancock S Schneider JJ Scott RJ Attia J Milward EA Prevalence of clinically actionable genotypes and medication exposure of older adults in the community Pharmacogenomics and Personalized Medicine Actionable genotype Community Older adults Pharmacogenomics Pre-emptive genotyping Single nucleotide polymorphism |
| title | Prevalence of clinically actionable genotypes and medication exposure of older adults in the community |
| title_full | Prevalence of clinically actionable genotypes and medication exposure of older adults in the community |
| title_fullStr | Prevalence of clinically actionable genotypes and medication exposure of older adults in the community |
| title_full_unstemmed | Prevalence of clinically actionable genotypes and medication exposure of older adults in the community |
| title_short | Prevalence of clinically actionable genotypes and medication exposure of older adults in the community |
| title_sort | prevalence of clinically actionable genotypes and medication exposure of older adults in the community |
| topic | Actionable genotype Community Older adults Pharmacogenomics Pre-emptive genotyping Single nucleotide polymorphism |
| url | https://www.dovepress.com/prevalence-of-clinically-actionable-genotypes-and-medication-exposure--peer-reviewed-article-PGPM |
| work_keys_str_mv | AT daneshin prevalenceofclinicallyactionablegenotypesandmedicationexposureofolderadultsinthecommunity AT hollidaye prevalenceofclinicallyactionablegenotypesandmedicationexposureofolderadultsinthecommunity AT hancocks prevalenceofclinicallyactionablegenotypesandmedicationexposureofolderadultsinthecommunity AT schneiderjj prevalenceofclinicallyactionablegenotypesandmedicationexposureofolderadultsinthecommunity AT scottrj prevalenceofclinicallyactionablegenotypesandmedicationexposureofolderadultsinthecommunity AT attiaj prevalenceofclinicallyactionablegenotypesandmedicationexposureofolderadultsinthecommunity AT milwardea prevalenceofclinicallyactionablegenotypesandmedicationexposureofolderadultsinthecommunity |